title: Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
abstract: PTH is in clinical use for the treatment of osteoporosis and is under intensive investigation for its potential in applications of tissue engineering, fracture healing, and implant integration. However, the mechanisms of its action to stimulate bone formation are still unclear. A novel bone tissue engineering model was used to elucidate basic mechanisms of PTH anabolic actions. Ectopic ossicles containing cortical bone, trabecular bone, and a hematopoietic marrow were generated from implanted bone marrow stromal cells (BMSC). One week after implantation, nude mice were administered PTH or vehicle for 1 week (group 1), 3 weeks (group 2), or 7 weeks (group 3). Another group was also treated for 3 weeks, initiated 12 weeks after implantation (group 4). Micro-radiography and histomorphometry revealed increased marrow cellularity in group 1 PTH-treated ossicles, increased bone in group 2 PTH-treated ossicles, and similar amounts of bone in both group 3 and 4 ossicles regardless of treatment. Incidence of phosphate mineral and phosphate mineral to hydroxyproline ratio via Raman spectroscopy were significantly higher after 3 weeks versus 1 week of PTH treatment, but there was no difference between PTH- and vehicle-treated ossicles. Early events of PTH action in group 1 ossicles and the effects of a single injection of PTH on 1- and 2-week-old ossicles were evaluated by Northern blot analysis. Osteocalcin (OC) mRNA was increased after 1 week of intermittent PTH treatment in ossicles and calvaria but an acute injection did not alter OC mRNA. In contrast, a single injection of PTH increased matrix gamma-carboxyglutamic acid protein (MGP) mRNA in 2-week-old ossicles. Differential and temporal-dependent effects of PTH on OC and MGP suggest at the molecular level, that PTH acts to inhibit osteoblast mineralization. However, this does not translate into tissue level alterations. These data indicate that anabolic actions of PTH in ectopic ossicles are temporally dependent on the BMSC implanted and suggest that cell implantation strategies are particularly responsive to PTH.
authors.affiliation: Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109-1078, USA.
authors.forename: Glenda J
authors.initials: GJ
authors.lastname: Pettway
authors.forename: Abraham
authors.initials: A
authors.lastname: Schneider
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Koh
authors.forename: Effendi
authors.initials: E
authors.lastname: Widjaja
authors.forename: Michael D
authors.initials: MD
authors.lastname: Morris
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Meganck
authors.forename: Steven A
authors.initials: SA
authors.lastname: Goldstein
authors.forename: Laurie K
authors.initials: LK
authors.lastname: McCauley
mesh_terms: D017667:Adipocytes / Q000166:cytology; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001854:Bone Marrow Cells / Q000166:cytology; D016026:Bone Marrow Transplantation; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000032:analysis; D002135:Calcium-Binding Proteins / Q000235:genetics; D002454:Cell Differentiation / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D006909:Hydroxyproline / Q000032:analysis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D015675:Osteocalcin / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010710:Phosphates / Q000032:analysis; D044168:Receptor, Parathyroid Hormone, Type 1 / Q000235:genetics; D012886:Skull / Q000378:metabolism; D013059:Spectrum Analysis, Raman; D013131:Spine / Q000033:anatomy & histology / Q000187:drug effects; D017154:Stromal Cells / Q000637:transplantation; D019379:Teriparatide / Q000008:administration & dosage / Q000494:pharmacology*; D023822:Tissue Engineering / Q000379:methods*; D014057:Tomography, X-Ray Computed; D000097568:Matrix Gla Protein
chemical_list: D045930:Anabolic Agents; D002118:Calcium; D002135:Calcium-Binding Proteins; D016326:Extracellular Matrix Proteins; D006909:Hydroxyproline; D015675:Osteocalcin; D010710:Phosphates; D044168:Receptor, Parathyroid Hormone, Type 1; D019379:Teriparatide; D000097568:Matrix Gla Protein